Clinical analysis of Moxifloxacin treatment for chronic obstructive pulmonary disease with acute exacerbation

Objective:To investigate the clinical effect of the moxifloxacin treatment for chronic obstructive pulmonary disease(COPD) with acute exacerbation.Methods:172 cases of chronic obstructive pulmonary disease in patients with acute exacerbation were randomly divided into two groups,the observation group for 86 cases,given Moxifloxacin intravenous injection 400 mg a day,to be treated for 5 days,then taken orally the moxifloxacin 400 mg one time a day,to be treated for 3 days;the control group for 86 cases and given intravenous levofloxacin 0.4 g one day,5 days later changed 0.2 g,and twice a day,continute using for 3 days;a course of observation group and control group therapy for 8 days;after 8 days,observed two groups patients with symptoms,signs,chest X-ray,as well as indicators such as changes in routine.Results:Moxifloxacin in the treatment of chronic obstructive pulmonary disease during acute exacerbation was significantly higher than the control group,the incidence of adverse reactions was 4.7% in the observation group,the control group was 10.5%.Conclusion:Moxifloxacin have a good effectiveness,safety and economic benefits in the treatment of chronic obstructive pulmonary disease with acute exacerbation,it is worth to promote clinical.